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Linoleic acid–good or bad for the brain?
Ameer Y. Taha1*
Increased intake of omega-6 rich plant oils such as soybean and corn oil over the past few decades has inadvertently tripled the
amount of n-6 linoleic acid (LA, 18:2n-6) in the diet. Although LA is nutritionally “essential”, very little is known about how it affects
the brain when present in excess. This review provides an overview on the metabolism of LA by the brain and the effects of excess
dietary LA intake on brain function. Pre-clinical evidence suggests that excess dietary LA increases the brain’s vulnerability to
inﬂammation and likely acts via its oxidized metabolites. In humans, excess maternal LA intake has been linked to a typical
neurodevelopment, but underlying mechanisms are unknown. It is concluded that excess dietary LA may adversely affect the brain.
The potential neuroprotective role of reducing dietary LA merits clinical evaluation in future studies.
npj Science of Food             (2020) 4:1 ; https://doi.org/10.1038/s41538-019-0061-9
INTRODUCTION
Linoleic acid (LA, 18:2n-6) is an essential n-6 polyunsaturated fatty
acid (PUFA)1 required for normal growth and development at 1 to
2% of daily energy.2 LA has become ubiquitous in Western diets
over the past few decades due to agricultural shifts towards high-
LA soybean and corn oils during the late 1930s, resulting in a
greater than 3-fold increase in intake.3,4 Historic levels of LA intake
ranged between 1 to 2% of daily calories pre-1930s, but currently
average more than 7% of daily calories.4 Based on economic
disappearance data, the majority of LA in the US diet comes from
soybean oil.4
Amongst other dietary PUFAs important for optimal health, LA
is the only one that has markedly changed in the diet over the
past few decades. Contrary to common misconception, the intake
of LA’s elongation-desaturation product, arachidonic acid (AA,
20:4n-6), and the essential n-3 fatty acid, alpha-linolenic acid (ALA,
18:3n-3), and its elongation-desaturation products eicosapentae-
noic acid (EPA) and docosahexaenoic acid (DHA), has remained
relatively constant at <1% energy since the early 1900s.4 Excess LA
in the food supply has shifted the n-6 to n-3 ratio from 4:1 to
20:1.4,5
Surprisingly, little is known about how this increase in dietary LA
affects the brain. It is mainly viewed as an essential precursor to
AA, which is important for neurodevelopment and other
physiological processes.6 Despite being a major part of the diet,
LA has been considered non-functional in the brain because of its
low concentration (<2% of total fatty acids) compared to palmitic
acid (16:0), stearic acid (18:0), oleic acid (18:1n-9), DHA, and AA
which make up over 84% of brain fatty acids in rats and
humans.7,8
LA is known to enter the brain at a rate of ~4 pmol/g/s, which is
comparable to the rate of entry of AA, DHA, and other fatty acids
into the brain.9,10 However, unlike AA and DHA which mostly
incorporate into brain membrane phospholipids, the majority
(~59%) of LA entering the brain is rapidly β-oxidized into aqueous
products, likely composed of carbon dioxide, acetate, and other
polar metabolites of β-oxidation.9 Some of the 2-carbon acetate
molecules produced by β-oxidation are recycled into cholesterol
via de novo lipid synthesis pathways within the brain.9,11
LA is also a precursor to oxidized products known as ‘oxidized
linoleic acid metabolites’ (OXLAMs) that are produced by auto-
oxidation or enzymatically via lipoxygenase (LOX), cyclooxygenase
(COX), cytochrome P450 (CYP450), and soluble epoxide hydrolase
(sEH).12–15 OXLAMs are lipid mediators known to regulate pain
and inﬂammatory signaling in peripheral tissue,16–19 where they
are abundant.18,20 In the brain, they are presumed to be formed
by LOX, COX, CYP450, and sEH enzymes, but their role there is not
fully understood.
This review highlights the current state of knowledge on the
role and metabolism of LA and OXLAMs in the brain. Studies
linking LA and OXLAMs to reported biochemical, neuropatholo-
gical, or behavioral endpoints in chickens, rodents, and humans
are discussed, and directions for future research are proposed.
EFFECTS OF LA OR OXLAMS ON CHICKENS
Studies in the late 1950s and 1970s showed that chicks fed a
vitamin (V)-E deﬁcient diet containing LA developed encephalo-
malacia,21–25 a neurodegenerative condition characterized by
necrosis, edema, and microvasculature abnormalities that can
lead to ataxia and death.26 Table 1 provides a detailed summary of
all these studies, which are discussed herein.
Dam et al. reported that 2-day-old chicks fed a V-E deﬁcient diet
containing 1.5% ethyl-LA (weight percent) from the 2nd day of life
onwards, died from encephalomalacia within 28 days (11 out of 12
chicks), compared to chicks fed a V-E deﬁcient diet containing
ethyl-ALA (0 out of 12) or a V-E deﬁcient basal diet lacking both LA
and ALA (0 out of 12).21 In a follow-up study, the authors found
that a V-E deﬁcient diet containing 1.5% ethyl-AA induced
encephalomalacia faster than a V-E deﬁcient diet containing
1.5% ethyl-LA or lard (mixed source of LA and AA).24 These studies
demonstrated that when V-E is absent from the diet, AA and to a
lesser extent LA, damage the brain of young chicks. ALA caused
no damage.
Follow-up studies in chickens demonstrated that oxidized LA
metabolites (i.e., OXLAMs) were the likely cause of encephaloma-
lacia, and that this effect was linked by maternal dietary LA
content. Bartov and Bornstein reported that maternal intake of a
4% soybean oil (relatively high in LA) or 4% tallow (low in LA) diet
containing 5 or 25mg/kg α-tocopherol acetate each, from 6 to
11 months of age, reduced egg-yolk LA concentration in the
tallow group (independent of V-E dietary content), and decreased
V-E concentration in yolk of both groups fed the tallow and
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soybean diets containing low α-tocopherol acetate (5 mg/kg).23
Chicks from each maternal group were then fed a V-E free diet
containing 4% or 10% oxidized safﬂower oil high in LA (~70%) for
31 days to induce encephalomalacia. Oxidation was achieved by
heating the oil at 145 °C for 24 h.
The authors reported that regardless of safﬂower oil content of
the chick diet (4 or 10% level), chicks born to hens that were fed
the 4% soybean oil diet containing low (5mg/kg) α-tocopherol
acetate levels experienced a signiﬁcantly higher frequency of
ataxia and mortality compared to chicks born hens fed 4%
soybean oil containing 25mg/kg α-tocopherol, or beef tallow
containing either 5 or 25mg/kg α-tocopherol.23 Hence, a high LA
maternal diet low in V-E accelerated the development of ataxia
and encephalomalacia-related mortality in chick offspring main-
tained on a V-E free diet containing oxidized safﬂower oil.
Lowering maternal dietary LA or supplementing it with V-E was
protective.
Budowski et al. performed a series of experiments to under-
stand the cause of ataxia and mortaility linked to encephaloma-
lacia.25 They fed a V-E free diet containing oxidized safﬂower oil or
non-heated safﬂower oil methyl esters at 4% or 10% (w/w) to
chicks for 2 to 3 weeks. At 4% oil content, the incidence of ataxia
and mortality were higher in the group fed the non-heated
safﬂower oil compared to the group fed oxidized safﬂower oil. At
10%, ataxia and mortality were higher in the group fed oxidized
safﬂower compared to the group fed non-heated safﬂower oil. The
ﬁndings suggest that in the absence of V-E, oxidized safﬂower oil
at 10% (w/w) induced more neurological deﬁcits than at 4%. Also,
the fact that ataxia and death were observed in the group fed 4%
non-heated safﬂower oil, suggests the absence of dietary V-E
might induce oil auto-oxidation of LA (the main PUFA in safﬂower
oil). It is not known whether the OXLAM species generated by
auto-oxidation due to the absence of V-E in the diet, differ from
those generated by heating. Notably, this study did not include a
control group provided with V-E in the diet.
To test whether V-E was protective, the authors provided 1-day-
old male chicks with non-heated or heated 10% (w/w) safﬂower
oil methyl esters lacking or containing 1 µg/kg V-E for 19 days.25
Ataxia and mortality were relatively high in the groups fed non-
heated oils lacking or containing V-E (65–70% ataxia; 20–30%
mortality). In the groups provided with oxidized oil with or
without V-E, the incidence of ataxia and mortality were much
increased (90–95% ataxia, 70% mortality), irrespective of V-E
content. It is possible that higher doses of V-E might have been
more effective in reducing mortality and the incidence of ataxia by
limiting auto-oxidation, particularly in the non-heated safﬂower
oil group.
The authors also introduced the polar fraction (at 0.3% w/w) to
the V-E free diet containing 4% safﬂower oil, and found that it
induced ataxia and increased mortality compared to the same
background diet lacking the polar extracts.25 Because oleic acid
and LA are the main unsaturated fatty acids in safﬂower oil, the
authors introduced oleic acid and LA derived ketone esters (i.e.,
oxidized fatty acids) at 0.2% and 0.12%, respectively, to the same
V-E free diets containing 4% safﬂower oil. They found that the
incidence of ataxia was 50% and 80% with the oleic acid and LA
keto-esters, respectively, and thus higher than the diets lacking
these oxidized compounds. A separate study by Kokatnur et al.
showed that the addition of 0.25% (w/w) 12-oxo-cos-9-octadece-
noic acid, 12-oxo-octadecanoic acid, 12-oxo-trans-10-octadece-
noic acid, or 12-oxo-cos-9-octadecenoic acid methyl ester to a V-E
deﬁcient basal diet containing 10% corn oil, induced encephalo-
malacia in 42–100% of chickens compared to 17% in those fed the
basal diet.27 The authors also determined that as little as 0.05% of
ketone fatty acids induced encephalomalacia and that this effect
was exacerbated by adding more corn oil to the diet (from 2.5 to
10% w/w).27 These studies provide direct evidence that OXLAMs,T
ab
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and to a lesser extent oxidized oleic acid metabolites, induce
ataxia and mortality due to encephalomalacia in chickens.
In the Budowski et al. study, the administration of the anti-
coagulant dicumarol to a V-E free diet containing 4% safﬂower oil
reduced the incidence of ataxia and mortality,25 suggesting that
the neurotoxic effects of OXLAMs may be caused by blood
coagulation and disturbances in the brain’s microvasculature. This
is in agreement with a study by Fischer et al. who showed
morphologic changes in cerebral vasculature, characteristic of pre-
ceroid formation in adult chickens fed an 8% LA diet lacking V-E,
compared to chickens on a similar diet containing V-E.22 Fully
developed ceroids have been linked to neurodegeneration.28
EFFECTS OF LA OR OXLAMS ON RODENTS
The few studies that explored the direct role of LA and its
metabolites in rodents have shown that LA is involved in
regulating brain immunity, seizure threshold, and neuronal
signaling, and that some of these effects are mediated by its
oxidized metabolites (i.e., OXLAMs).
In rats, LA lowering was found to attenuate LPS-induced
neuroinﬂammation, reduce brain concentration of pro-
inﬂammatory lipid autacoids and increase brain levels of anti-
inﬂammatory lipid mediators. Taha et al. reported that compared
to a “high” 5.2% energy LA diet, chronic consumption of a “low”
0.4% energy LA diet for 15–18 weeks, reduced the incorporation
rate of radiolabeled AA into the brain and prevented the increase
in brain AA-derived prostaglandin E2 concentration and COX-2
activity induced by 2-day lipopolysaccharide (LPS) administration
into the 4th ventricle.29 Two independent studies reported that
dietary LA lowering (from 5.2% to 0.4% energy) reduced brain
concentrations of pro-inﬂammatory AA-derived eicosanoids (e.g.,
5-Hydroxyeicosatetraenoic acid) and increased concentrations of
anti-inﬂammatory EPA or DHA derived metabolites.30,31 This may
partially explain why LA lowering increased resilience to LPS-
induced neuroinﬂammation in the Taha et al. study.29
Acute administration of LA was reported to confer seizure
protection in rats. When infused intravenously at a dose of
0.028mg/kg, it decreased the incidence of tonic-clonic convul-
sions by 3-fold, but increased the incidence of cortical spike-wave
discharges by 1.5 to 2 folds.32 Voskuyl et al. showed that
intravenous administration of 56–64mg/kg LA raised cortical
focal and generalized seizure thresholds by 3-fold and 1.3–9.0-
fold, respectively, in a cortical stimulation seizure model compared
to saline and oleic acid controls.33 The effect of chronic LA
administration on seizure thresholds has not been tested.
Recent studies suggest that the effects of LA in the brain are
likely mediated by OXLAMs. Hennebelle et al. showed that
OXLAMs are increased in various rat brain regions following acute
ischemic injury, possibly due to their involvement in the response
to ischemic brain injury.34 Direct application of LA itself to rat
hippocampal slices did not alter paired-pulse facilitation within
soma or dendrites, whereas LA-derived 13-hydroxyoxtadecadieo-
nic acid (13-HODE) increased somatic paired pulse facilitation.34
Although the Hennebelle et al. study raises the possibility that LA’s
effects on the brain might be mediated by OXLAMs,34 it only
tested one OXLAM (13-HODE). Future studies should address the
isolated and collective effects of other hydrox, epoxy, dihydroxy,
trihydroxy, and ketone metabolites of LA on neurotransmission
and other brain processes.
Although OXLAMs are known to be abundant in rodent
brain,31,34 it is not known whether they are preferentially formed
in the brain from LA, or incorporated directly from circulating
OXLAMs provided in the diet. This issue was recently addressed by
two studies. Taha et al. fed rats a graded LA diet (0.4%, 5.2%, and
10.4% energy) for 15–18 weeks, and showed that increasing
dietary LA increased cerebral cortex and cerebellum OXLAM
concentrations in a dose-dependent manner (Fig. 1).31 In a follow
up study, Ramsden et al. fed mice a high LA diet (17% energy), or
a low LA diet (4% energy) with or without oxidized corn oil as a
source of OXLAMs.35 The authors found no evidence of dietary
OXLAM incorporation into the brain, but consistent with a
previous report, the high LA diet increased brain OXLAM
concentrations compared to the low LA diet with or without
OXLAMs.35 These studies suggest that dietary OXLAMs are not
readily incorporated into rodent (mouse) brain, and that LA is the
main source of OXLAMs in the brain. Behavioral studies on dietary
OXLAMs in rodents are yet to be performed, as has been done
previously in chickens. Notably, although the chicken studies
outlined in Table 1 showed an effect of OXLAMs on behavior,
none assessed their bioavailability. In rodents, dietary LA
hydroperoxides were reported to degrade into aldehydes in the
stomach, raising the possibility that the reported effects of
OXLAMs on the brain might be mediated by their degradation
products.36
EFFECTS OF LA OR OXLAMS ON HUMANS
Most of the clinical evidence on the effects of LA on the brain
stem from epidemiological studies. One prospective cohort study
reported an inverse association between high PUFA intake and
mortality linked to neurodegenerative disease.37 Although it is
difﬁcult to establish causation with such studies, the same study,
found no association between LA on neurodegenerative disorders
after adjusting for confounders using multi-variate analysis, but
reported a signiﬁcant 4–15% risk reduction in neurodegeneration
with increased AA, ALA, or EPA and DHA intake.37 Randomized
controlled trials are needed to conﬁrm these ﬁndings.
Ramsden et al. reported that dietary LA lowering from 7% to 2%
energy combined with a high EPA and DHA diet (~1.5 g per day)
for 12 weeks, reduced migraine frequency and improved quality
of life in patients with drug-resistant migraines.38,39 Lowering
dietary LA without changing EPA and DHA did not signiﬁcantly
alter migraine frequency or improve quality of life.38,39 Although
this study did not have a parallel group that received EPA and
DHA alone, it provides evidence of a potential synergistic beneﬁt
to lowering LA and increasing EPA and DHA simultaneously.40 It is
possible that longer-term LA lowering regimens might reduce
migraine frequency as well, although this remains to be tested.
Several epidemiological studies explored the role of LA on
neurodevelopment. Like other dietary fatty acids, LA accumulates
Fig. 1 Effect of increasing dietary linoleic acid (LA) on unesteriﬁed
oxidized linoleic acid metabolite (OXLAM) concentrations in rat
cerebral cortex. Adapted from Taha et al.,31 EpOME epoxyoctadeca-
monoenoic acid, THF tetrahydrofuran-diols, EKODE epoxyketoocta-
decenoic acid, HODE hydroxyoctadecadienoic acid, oxo-ODE Oxo-
octadecadienoic acid, DiHOME dihydroxyoctadecamonoenoic acid,
TriHOME trihydroxyoctadecamonoenoic acid. Data are graphed as
median and interquartile interval (IQR) representing the 25th and
75th percentiles. *p < 0.05 compared to 0.4% LA group by
Kruskall–Wallis test.
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in breast milk, which is the primary source of infant nutrition for
the ﬁrst few months months of life.41 Thus, consistent with the
increase in dietary LA in the food supply, breastmilk LA
composition has increased from 7% to 12% of total fatty acids
between 1970 and 2000.41,42 The 12% composition value
corresponds to 8% energy, which exceeds the minimum 1–2%
energy required for developing infants by 4–8-fold.2
Overall, studies have shown an adverse effect of maternal
breast milk or dietary LA on neurodevelopment. One study
reported that a high maternal breast milk LA percent composition
(>9.7% of fatty acids) was associated with reduced motor and
cognitive scores in 2- to 3-year-old infants.43 In the same cohort,
maternal breastmilk LA percent composition was associated with
reduced verbal IQ at 5 to 6 years of age.44 In fact, children
breastfed with the highest levels of LA had cognitive scores
comparable to children who were never breastfed.43 These effects
were independent of AA or DHA breast milk composition,
suggesting a direct impact of excess breast milk LA (and hence
maternal intake) on brain development. Consistent with these
ﬁndings, Lassek and Gaulin found an inverse correlation between
breast milk LA percent composition and cognitive scores in 15-
year-old children, suggesting a long-lasting impact of maternal LA
on offspring cognitive skills.45 Steenweg-de Graaff et al. also
reported a signiﬁcant positive association between maternal
plasma LA composition measured at mid-pregnancy and the risk
of autistic traits in children at the age of 6 years.46 A more recent
study found that prenatal intake of diets high in the ratio of LA to
ALA, was associated with a 2-fold increase in the risk of delayed
psychomotor and mental developmental in 6 months infants.47
CONCLUSION
Pre-clinical and clinical studies dispel previous assumptions that
LA is a benign fatty acid in the brain. On the contrary, when
present in excess and chronically, it induces ataxia in chickens,
promotes neuroinﬂammation in rats and is linked to abnormal
neurodevelopment in humans. LA administered acutely to rats
confers seizure protection, although its chronic effects on seizures
has not been tested.
Recent animal studies suggest that the effects of LA might be
mediated by OXLAMs generated from LA entering the brain.
Although OXLAMs are present in the diet,48 the extent of their
bioavailability and accumulation in the brain from dietary sources
appears to be minimal.35,36 However, further assessment of their
degradation products on brain neurophysiology and other organs
is warranted.
Chronic consumption of low LA diets might protect the brain
against inﬂammation, as evidenced by rat studies showing an anti-
inﬂammatory lipidome in the brains of rats fed a low LA diet,29–31
and human studies showing that LA lowering combined with EPA
and DHA reduced headache frequency in patients with drug-
resistant migraines.38,39
In conclusion, this review presents evidence that excess LA in
the food supply might adversely affect the brain. The potential
beneﬁt of LA lowering merits detailed evaluation in well-designed
and adequately-powered clinical studies, to test whether this
translates into tangible reductions in the risk of neurodegenera-
tive disorders and neurodevelopmental abnormalities at a
population level.
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